ClinicalTrials.gg
TerminatedNCT00912509Updated Nov 22, 2017Results posted

Cross Linking for Treatment of Corneal Infection

An interventional study of riboflavin and UVX Light in Infectious Keratitis, sponsored by Price Vision Group. Terminated at 1 site in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2017-11-22.

Sponsored by Price Vision Group · Not applicable, Interventional, and Treatment

Why this study was terminated
insufficient efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Corneal Ulcer with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Corneal Ulcer · United States.

Enrollment
15th of 19
30 · median 150
Started
2009
the only one that year
No phase
3 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
1 of 22
Price Vision Group

Among the 22 studies in Corneal Ulcer with a site in United States, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2009, is one of 3 with no phase, and was the 5th registered.

Corneal Ulcer

63 studies on the registry are indexed under Corneal Ulcer; 8 are open to participants now.

Browse Corneal Ulcer studies →

Open to participants now

4 of the 22 studies in Corneal Ulcer with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Corneal Ulcer studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Corneal Ulcer with a site in United States, or all of them as a file.
02

Study summary

This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal cross linking system to treat corneal infections.

03

Conditions studied

  • Infectious Keratitis

Browse trials for

Keywords

  • infectious keratitis
  • cross linking
  • corneal ulcer
  • corneal infection
  • collagen cross linking
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of infectious keratitis

Exclusion criteria

Exclusion Criteria:

  • corneal ulcer that has perforated
  • corneal ulcer that has produced a descemetocele
  • women who are pregnant or breastfeeding
  • patients who are or unwilling or unable to comply with a medication regimen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    30 minute light duration

    30 minute treatment with UVX light

    Drug: riboflavin · Device: UVX Light

  • Active comparator
    45 minute light duration

    45 minute treatment with UVX light

    Device: UVX Light

Interventions

  • riboflavin 0.1% is applied every 2 minutes for 30 minutes

  • DeviceUVX Light

    UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%

06

What researchers measure

Primary outcomes

  1. Time to Re-epithelialization

    Time frame: Day 1, day 2, day 3, day 4, day 5, day 6, day 7, week 2, and subsequent weekly assessments until re-epithelialization is complete

Secondary outcomes

  1. Time to Resolution of Stromal Infiltration

    Time frame: day 1, day 2, day 3, day 4, day 5, day 6, day 7, week 2, and subsequent weekly assessments until infiltrate is completely resolved

07

Results

Posted Aug 22, 2014

Participant flow

Participant flow — Overall Study
Milestone30 Minute Light Duration45 Minute Light Duration
Started2010
Completed157
Not completed53
Withdrew: Lost to follow-up10
Withdrew: Lack of efficacy43

Outcome measures

PrimaryTime to Re-epithelialization
Time frame:
Day 1, day 2, day 3, day 4, day 5, day 6, day 7, week 2, and subsequent weekly assessments until re-epithelialization is complete
Reported as:
Median · Days
Time to Re-epithelialization
Days30 Minute Light Duration45 Minute Light Duration
Time to Re-epithelialization14 (6 to 28)11 (6 to 29)
SecondaryTime to Resolution of Stromal Infiltration
Time frame:
day 1, day 2, day 3, day 4, day 5, day 6, day 7, week 2, and subsequent weekly assessments until infiltrate is completely resolved
Reported as:
Median · days
Time to Resolution of Stromal Infiltration
days30 Minute Light Duration45 Minute Light Duration
Time to Resolution of Stromal Infiltration21 (8 to 33)10 (7 to 11)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
30 Minute Light Duration—0/20 (0%)5/20 (25%)
45 Minute Light Duration—0/10 (0%)4/10 (40%)
Most frequent other events
Most frequent other events
Event30 Minute Light Duration45 Minute Light Duration
Cornea transplantEye disorders4/202/10
Intracorneal injection of voriconazoleEye disorders1/201/10
Dendritic lesions characteristic of prior herpes simplexEye disorders0/201/10

Baseline characteristics

This is the number of participants who were culture-positive

Age, Categorical
Age, Categorical(Participants)30 Minute Light Duration45 Minute Light DurationTotal
<=18 years101
Between 18 and 65 years13417
>=65 years6612
Sex: Female, Male
Sex: Female, Male(Participants)30 Minute Light Duration45 Minute Light DurationTotal
Female14620
Male6410
08

Study locations

1 site
  • Price Vision Group
    Indianapolis, Indiana 46260, United States
09

References and documents

Publications

  • Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008 Jun;27(5):590-4. doi: 10.1097/ICO.0b013e318169d698. PubMed 18520510 ↗
  • Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW Jr. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012 Oct;28(10):706-13. doi: 10.3928/1081597X-20120921-06. PubMed 23062001 ↗
  • Davis SA, Bovelle R, Han G, Kwagyan J. Corneal collagen cross-linking for bacterial infectious keratitis. Cochrane Database Syst Rev. 2020 Jun 17;6(6):CD013001. doi: 10.1002/14651858.CD013001.pub2. PubMed 32557558 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2009
First posted
Jun 3, 2009
Start
May 2009
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 22, 2014
Last update
Nov 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00912509
Lead sponsor
Price Vision Group
Collaborators
Cornea Research Foundation of America
Responsible party
Sponsor
First posted
Jun 3, 2009
Start date
May 2009
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 22, 2014
Last update
Nov 22, 2017

Study contacts

Francis W Price, MD
principal investigator · Price Vision Group

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion